Alamar Biosciences (NASDAQ:ALMR) Shares Gap Down on Insider Selling

Posted by Brian Himes on Nov 4th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report)’s share price gapped down before the market opened on Wednesday following insider selling activity. The stock had previously closed at $30.22, but opened at $28.02. Alamar Biosciences shares last traded at $27.89, with a volume of 117,911 shares traded.

Specifically, major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $29.84, for a total value of $1,310,871.20. Following the completion of the sale, the insider directly owned 160,913 shares in the company, valued at $4,801,643.92. The trade was a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Corporate Gp Vi Ltd. Qiming sold 143,706 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $30.38, for a total transaction of $4,365,788.28. Following the completion of the sale, the insider directly owned 161,679 shares of the company’s stock, valued at approximately $4,911,808.02. This trade represents a 47.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In other Alamar Biosciences news, major shareholder Corporate Gp Vi Ltd. Qiming sold 100,837 shares of the stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49. Following the transaction, the insider directly owned 164,191 shares in the company, valued at $5,380,539.07. This represents a 38.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Wall Street Analyst Weigh In

A number of research firms have commented on ALMR. JPMorgan Chase & Co. raised their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Stifel Nicolaus upped their price target on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Finally, Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alamar Biosciences currently has a consensus rating of “Hold” and an average target price of $31.80.

View Our Latest Stock Analysis on ALMR

Key Headlines Impacting Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: Alamar reported a third-quarter loss of $0.19 per share, narrower than analysts’ expected $0.22 loss, on revenue of $33.55 million. The company also raised its 2026 revenue guidance, strengthening the growth outlook. Alamar Q3 results and guidance
Positive Sentiment: A scientific collaboration with GSK will use Alamar’s NULISA platform to study protein signatures across multiple disease areas. The partnership could increase visibility and validation of the technology, though no financial terms were disclosed. GSK collaboration announcement
Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study of neurodegenerative disease. The large research project could showcase Alamar’s platform, although its direct commercial impact is not specified. UK Biobank study announcement
Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming has continued selling shares, including 43,930 shares on Nov. 2 and 143,706 on Oct. 30, alongside additional sales in October. The transactions may weigh on sentiment; no reason for the sales was disclosed. SEC filing on shareholder sales

Alamar Biosciences Price Performance

The business’s 50-day moving average price is $30.49. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.80 billion and a P/E ratio of -13.23.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. The firm had revenue of $33.55 million during the quarter. Equities analysts anticipate that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALMR. China Universal Asset Management Co. Ltd. bought a new position in shares of Alamar Biosciences during the 3rd quarter worth approximately $196,000. Squarepoint Ops LLC purchased a new stake in Alamar Biosciences during the second quarter valued at approximately $283,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares during the last quarter. State Street Corp acquired a new stake in Alamar Biosciences in the second quarter valued at approximately $3,930,000. Finally, Wellington Management Group LLP acquired a new stake in Alamar Biosciences in the second quarter valued at approximately $12,407,000.

Alamar Biosciences Company Profile

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.